Status:
COMPLETED
Encouraging Flu Vaccination Among High-Risk Patients Identified by ML
Lead Sponsor:
Geisinger Clinic
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Influenza
Vaccination
Eligibility:
All Genders
17+ years
Phase:
NA
Brief Summary
The purpose of the current study is to test different interventions to determine the most effective way to promote flu vaccine uptake in a high-risk population identified by an "artificial intelligenc...
Detailed Description
Background On average, 8% of the US population gets sick from flu each flu season (Tokars et al. 2018). Since 2010, the annual disease burden of influenza has included 9-45 million illnesses, 140,000...
Eligibility Criteria
Inclusion
- Current Geisinger patient at the time of study
- Falls in the top 10% of patients at highest risk, as identified by the flu-complication risk scores of Medial's machine learning algorithm (which operates on coded EHR data)
- May limit inclusion to patients that are under Geisinger primary care, depending on algorithm performance of patients who have non-Geisinger PCPs
Exclusion
- Has contraindications for flu vaccination
- Has opted out of receiving communications from Geisinger via all of the modalities being tested
Key Trial Info
Start Date :
September 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 21 2021
Estimated Enrollment :
117649 Patients enrolled
Trial Details
Trial ID
NCT04323137
Start Date
September 21 2020
End Date
September 21 2021
Last Update
December 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geisinger
Danville, Pennsylvania, United States, 17822